BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1856 related articles for article (PubMed ID: 33558079)

  • 1. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
    Zahr N; Urien S; Llopis B; Pourcher V; Paccoud O; Bleibtreu A; Mayaux J; Gandjbakhch E; Hekimian G; Combes A; Benveniste O; Saadoun D; Allenbach Y; Pinna B; Cacoub P; Funck-Brentano C; Salem JE
    Therapie; 2021; 76(4):285-295. PubMed ID: 33558079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.
    Garcia-Cremades M; Solans BP; Hughes E; Ernest JP; Wallender E; Aweeka F; Luetkemeyer AF; Savic RM
    Clin Pharmacol Ther; 2020 Aug; 108(2):253-263. PubMed ID: 32285930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease.
    Mallat J; Hamed F; Balkis M; Mohamed MA; Mooty M; Malik A; Nusair A; Bonilla MF
    Medicine (Baltimore); 2020 Dec; 99(52):e23720. PubMed ID: 33350752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
    Steinbronn C; Chhonker YS; Stewart J; Leingang H; Heller KB; Krows ML; Paasche-Orlow M; Bershteyn A; Stankiewicz Karita HC; Agrawal V; Laufer M; Landovitz R; Wener M; Murry DJ; Johnston C; Barnabas RV; Arnold SLM
    Clin Transl Sci; 2023 Jul; 16(7):1243-1257. PubMed ID: 37118968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.
    Ruiz S; Concordet D; Lanot T; Georges B; Goudy P; Baklouti S; Mané C; Losha E; Vinour H; Rousset D; Lavit M; Minville V; Conil JM; Gandia P
    Int J Antimicrob Agents; 2021 Feb; 57(2):106247. PubMed ID: 33259916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxychloroquine (HCQ) Treatment for Hospitalized Patients with COVID- 19.
    Tsanovska H; Simova I; Genov V; Kundurzhiev T; Krasnaliev J; Kornovski V; Dimitrov N; Vekov T
    Infect Disord Drug Targets; 2022; 22(6):e030322201650. PubMed ID: 35240966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.
    Gerlovin H; Posner DC; Ho YL; Rentsch CT; Tate JP; King JT; Kurgansky KE; Danciu I; Costa L; Linares FA; Goethert ID; Jacobson DA; Freiberg MS; Begoli E; Muralidhar S; Ramoni RB; Tourassi G; Gaziano JM; Justice AC; Gagnon DR; Cho K
    Am J Epidemiol; 2021 Nov; 190(11):2405-2419. PubMed ID: 34165150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.
    Tai TT; Wu TJ; Wu HD; Tsai YC; Wang HT; Wang AM; Shih SF; Chen YC
    Clin Transl Sci; 2021 Jan; 14(1):132-136. PubMed ID: 33135382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
    de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
    Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.
    Cui C; Tu S; En VSJ; Li X; Yao X; Li H; Liu D
    Curr Drug Metab; 2020; 21(6):427-435. PubMed ID: 32520683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial.
    Byakika-Kibwika P; Sekaggya-Wiltshire C; Semakula JR; Nakibuuka J; Musaazi J; Kayima J; Sendagire C; Meya D; Kirenga B; Nanzigu S; Kwizera A; Nakwagala F; Kisuule I; Wayengera M; Mwebesa HG; Kamya MR; Bazeyo W
    BMC Infect Dis; 2021 Dec; 21(1):1218. PubMed ID: 34872511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
    Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
    Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
    Satlin MJ; Goyal P; Magleby R; Maldarelli GA; Pham K; Kondo M; Schenck EJ; Rennert H; Westblade LF; Choi JJ; Safford MM; Gulick RM
    PLoS One; 2020; 15(7):e0236778. PubMed ID: 32701969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
    Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
    Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial.
    Agusti A; Guillen E; Ayora A; Anton A; Aguilera C; Vidal X; Andres C; Alonso M; Espuga M; Esperalba J; Gorgas MQ; Almirante B; Ribera E
    Enferm Infecc Microbiol Clin (Engl Ed); 2022; 40(6):289-295. PubMed ID: 35680347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.